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Abstract
Background:  Patients with HIV are subject to development of HIV metabolic syndrome
characterized by dyslipidemia, lipodystrophy and insulin resistance secondary to highly active
antiretroviral therapy (HAART). Rosuvastatin is a highly potent HMG-CoA reductase inhibitor.
Rosuvastatin is effective at lowering LDL and poses a low risk for drug-drug interaction as it does
not share the same metabolic pathway as HAART drugs. This study sought to determine the
efficacy of rosuvastatin on lipid parameters in HIV positive patients with HIV metabolic syndrome.
Results: Mean TC decreased from 6.54 to 4.89 mmol/L (25.0% reduction, p < 0.001). Mean LDL-
C decreased from 3.39 to 2.24 mmol/L (30.8% reduction, p < 0.001). Mean HDL rose from 1.04 to
1.06 mmol/L (2.0% increase, p = ns). Mean triglycerides decreased from 5.26 to 3.68 mmol/L (30.1%
reduction, p < 0.001). Secondary analysis examining the effectiveness of rosuvastatin monotherapy
(n = 70) vs. rosuvastatin plus fenofibrate (n = 43) showed an improvement of 21.3% in TG and a
decrease of 4.1% in HDL-C in the monotherapy group. The rosuvastatin plus fenofibrate showed
a greater drop in triglycerides (45.3%, p < 0.001) and an increase in HDL of 7.6% (p = 0.08).
Conclusion: This study found that rosuvastatin is effective at improving potentially atherogenic
lipid parameters in HIV-positive patients. The lipid changes we observed were of a smaller
magnitude compared to non-HIV subjects. Our results are further supported by a small, pilot trial
examining rosuvastatin effectiveness in HIV who reported similar median changes from baseline of
-21.7% (TC), -22.4% (LDL-C), -30.1% (TG) with the exception of a 28.5% median increase in HDL.
In light of the results revealed by this pilot study, clinicians may want to consider a possible
resistance to statin therapy when treating patients with HIV metabolic syndrome.
Background
Patients with HIV are subject to dyslipidemia and other
complications secondary to their highly active antiretrovi-
ral therapy (HAART) that are often classified as HIV met-
abolic syndrome [1-3]. As a result, these patients are at an
increased risk for cardiovascular events such as myocar-
dial infarction [4-6]. Currently pravastatin, atorvastatin
and fluvastatin are recommended for treatment of
HAART-related dyslipidemia as they pose a low-risk of
pharmacological interaction with ongoing HAART [7,8].
Rosuvastatin is a highly potent 3-hydroxy-3-methylglu-
taryl coenzyme A (HMG-CoA) inhibitor and is not metab-
olised by the Cytochrome P3A4 (CYP3A4) enzyme
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system, which is frequently inhibited by certain HAART
therapies. The lack of requirement of CYP3A4 metabolism
for rosuvastatin makes it an attractive lipid-lowering drug
to treat the dyslipidemia associated with HAART [9]. To
date only one study has examined the effect of rosuvasta-
tin for treatment of HAART-related dyslipidemia wherein
Calza et al determined that rosuvastatin effectively low-
ered total cholesterol (TC), LDL-cholesterol (LDL-C) and
triglycerides (TG) while raising HDL-cholesterol (HDL-C)
in HIV+ patients [10].
Elucidating any resistance to this new, potent statin would
be of great clinical importance given the potential for wide
use of rosuvastatin in this population, which is considered
to be at moderate risk for cardiovascular disease.
Results
Lipid analysis
The overall effect of rosuvastatin on lipid parameters was
as follows: TC decreased from 6.54 to 4.89 mmol/L
(25.0% reduction, p < 0.001). Mean triglycerides
decreased from 5.26 to 3.68 mmol/L (30.1% reduction, p
< 0.001). Mean LDL decreased from 3.39 to 2.34 mmol/L
(30.8% reduction, p < 0.001). Mean HDL rose from 1.04
to 1.06 mmol/L (2.0% increase, p = ns). Mean TC:HDL
decreased from 7.22 to 5.03 (30.3%, p < 0.001). Mean
apolipoprotein B decreased from 1.30 to 0.97 g/L (25.3%
decrease, p < 0.001). The serum triglycerides of 33
patients were significantly elevated thus precluding calcu-
lation of serum LDL-C concentration. Five (5) patients
experienced adverse events that ultimately led to discon-
tinuation of the medication but were included in the
study as they remained on the medication for longer than
4 weeks prior to being discontinued. Three (3) patients
were discontinued due to elevated liver enzymes and 2
patients were discontinued due to complaints of muscle
soreness.
Dose-response analysis
A dose-response analysis was conducted wherein patients
on rosuvastatin monotherapy (n = 68) were subdivided
based on current rosuvastatin dosage. The 10 mg sub-
group (n = 45) showed a greater improvement across all
lipid parameters relative to the 20 mg subgroup (n = 23)
with the exception of HDL (figure 1). Only the change in
TC:HDL ratio was significant (p = 0.05). Patients taking
rosuvastatin 5 mg (n = 1) or 40 mg (n = 1) were not
included in this analysis.
Combination therapy vs. monotherapy
Secondary analysis examined the effectiveness of a regime
consisting of rosuvastatin as the sole lipid-lowering med-
ication (rosuvastatin monotherapy, n = 70) vs. patients in
whom rosuvastatin has been added onto their fenofibrate
regime (combination therapy, n = 42) (Fig. 2). Patients on
combination therapy showed a more significant drop in
triglycerides (45.3% vs. 21.3%, p = 0.001) and TC:HDL
(33.9% vs. 26.9%, p < 0.05) compared to patients on
monotherapy. Additionally, patients on monotherapy
showed a decrease in HDL of 4.1% compared to an
increase of 7.6% in the combination therapy group (p =
0.08). All lipid parameters in both groups showed an
improvement following addition of rosuvastatin when
compared to baseline with the aforementioned exception
of HDL in the monotherapy group.
Discussion
While this study found that rosuvastatin is indeed effec-
tive at improving potentially atherogenic lipid parameters
in HIV+ patients, an emerging theme from our results is
an apparent resistance to therapy in our study population
relative to previous studies involving non-HIV+ patients.
Previous studies have shown statins and fibrates to be less
effective in people with HIV compared to healthy subjects
indicating possible resistance to lipid lowering therapy
inherent to the virus itself or HAART [11,12]. As rosuvas-
tatin has previously been shown to be effective in non-
HIV populations both with and without the metabolic
syndrome, when compared to other statins, we would
expect an improvement of a similar magnitude in our
study. However, this was not the case [13-20].
One large randomised clinical trial examining the effec-
tiveness of rosuvastatin, in a non-HIV population, in com-
parison to other statins at improving plasma lipids noted
improvements of -33.6% for TC, -46.7% for LDL-C,
+9.3% for HDL-C and -23.4% for TG from baseline in
patients with metabolic syndrome taking rosuvastatin (n
= 240) [13]. By comparison in our study we saw changes
from baseline of -25.1% (p < 0.001), -31.5% (p < 0.001),
-4.1% (p < 0.05) and -21.3% for TC, LDL-C, HDL-C and
Dose-response analysis Figure 1
Dose-response analysis. Dose response analysis showing 
percentage change from baseline across all lipid parameters 
for 10 mg rosuvastatin monotherapy vs. 20 mg rosuvastatin 
monotherapy. * indicates p < 0.05.
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TG respectively for patients on rosuvastatin monotherapy
(n = 70). The most striking observations were the drop in
HDL-C and the blunted improvement across all other
lipid parameters.
The only other study examining the effects of rosuvastatin
in an HIV+ population also showed improvements that
were not as significant as would be expected from this
highly potent statin. Calza et al randomised HIV+ patients
to rosuvastatin or placebo for 24 weeks (n = 16) and
reported median changes from baseline of -21.7% (TC), -
22.4% (LDL-C) and -30.1% (TG) in atherogenic lipid
lowering parameters, along with a 28.5% median increase
in HDL [10]. These results are similar to ours with the
exception of the drastic difference in change in HDL-C.
This lack of effect of rosuvastatin on HDL is a novel find-
ing in the face of previous studies who found that rosuv-
astatin improves HDL in both HIV and non-HIV
populations [10,13]. In the present study the dyslipi-
demia is a drug-induced dyslipidemia the mechanism of
which is still not well understood. The lack of effect on
HDL may be related to an underlying cause of dyslipi-
demia induced by HIV itself.
Our dose response analysis (Fig. 1) showed very little dif-
ference between the 10 and 20 mg doses of rosuvastatin.
Despite only the TC:HDL ratio showing a statistically sig-
nificant improvement in the 10 mg group (-32.5% vs. -
19.4%) these findings support the possibility of an under-
lying mechanism of resistance to statin therapy in HIV+
patients.
Resistance to statin therapy is not unique to rosuvastatin
as evidenced by studies examining the effects of pravasta-
tin in the HIV population. These studies observed no bet-
ter than a 20.4% decrease in LDL-C compared to a 32.7%
decrease in the general population. In each case the treat-
ment group was given pravastatin 40 mg [21-23].
Protease inhibitor (PI)-containing HAART is often cited as
a cause dyslipidemia and lipodystrophy in HIV patients
and could possibly be the underlying cause of resistance
to therapy observed in this study [1,2,4]. In the present
study sub-analysis was conducted wherein patients were
stratified according to their current HAART regimen and
there did appear to be a less pronounced effect on lipid
parameters, especially TC and LDL, in patients on PI-con-
taining regimens. However there was no statistical signifi-
cance between the groups for any given lipid
measurement likely owing to the fact that the number of
patients on non-PI-containing regimens (n = 14) was so
much smaller than those on PI-containing regimens (n =
109) (data not shown). Other traditional explanations for
the lack of effect rosuvastatin shown in our study include
interaction with antacids, reduced compliance and lack of
financial resources. These explanations, while valid in cer-
tain populations, are unlikely for the present study as all
patients at our clinic are advised against taking antacids by
the resident pharmacist. Furthermore the pharmacist
reviews each patient's drug compliance every three
months and has found that, generally, patients in our
clinic are very compliant. Finally, in this center, the cost of
rosuvastatin is covered by the provincial drug formulary
and lack of financial resources should not play a role in
patient compliance.
The current published guidelines recommend diet and
exercise counselling, alteration of ARV regimen or adding
lipid lowering medications for dyslipidemia in patients
on ARV therapy [7]. A statin is suggested for LDL-C eleva-
tions and a fibrate is suggested for serum triglycerides ele-
vation. In the face of possible resistance to rosuvastatin
therapy in the HIV population a combination therapy
approach of rosuvastatin plus fibrate may be a wise option
to consider. The secondary analysis in this study assessed
patients on combination therapy, specifically rosuvastatin
with fenofibrate (Fig. 2). The combination therapy group
showed an improvement in both triglycerides (45.3% vs.
23.4%, p < 0.05) and TC:HDL ratio (33.9% vs. 26.0%, p
< 0.05) over the monotherapy group, with the latter
driven by a non-significant difference in HDL. The addi-
tion of rosuvastatin to existing fenofibrate therapy seems
promising especially given these improvements as well as
the accompanying though non-significant increase in
HDL-C in the combination therapy group. Although this
increase HDL-C is modest (7.6%) it is more encouraging
than the drop of 4.1% observed in the monotherapy
group. While the improvements in the combination
group can be perceived as less than expected it should be
kept in mind that this study was observational in nature.
Patients on combination therapy were likely treated as
Rosuvastatin monotherapy vs. Combination therapy Figure 2
Rosuvastatin monotherapy vs. Combination therapy. 
The percentage changes from baseline in lipid parameters of 
HIV+ patients taking either Rosuvastatin (R) and Fenofibrate 
(F) combination therapy or Rosuvastatin monotherapy. * 
indicates p < 0.05.
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such because their dyslipidemia proved resistant to initial
therapy and a more aggressive approach was deemed nec-
essary.
Conclusion
The resistance to therapy evidenced by the primary lipid
analysis and the dose-response analysis of this study is of
importance to clinicians treating HIV dyslipidemia as it
demonstrates that simply increasing the dosage of rosuv-
astatin may not be the most effective way to improve lipid
parameters in this population. Rosuvastatin is well suited
for the treatment of HIV dyslipidemia as it is not metabo-
lised by the CYP3A4 pathway, therefore, we suggest that
clinicians consider a combination approach involving
low dose rosuvastatin (i.e. 10 mg) in combination with
either a fibrate or ezetimibe as data presented here and
previously published data suggest that these combina-
tions are effective [9,24].
Methods
Study design/Setting
A retrospective analysis was undertaken to determine the
effect of rosuvastatin on the lipid profile of patients with
HIV.
All patients were seen at the Immunodeficiency Clinic/
HIV Metabolic Clinic (IDC/HIVMC) at St. Paul's Hospital,
Vancouver, BC, Canada. This is a tertiary referral center
where over 700 patients receive care for HIV associated
metabolic disorders. Patients who were treated with rosu-
vastatin between January 2003 and July 2006 were
included in the analysis. Rosuvastatin therapy was initi-
ated either as an alternative to a previously prescribed sta-
tin that proved ineffective, either alone or in combination
with other lipid lowering therapy, as an add-on to the
patient's current lipid lowering therapy or as mono-
therapy to statin-naïve patients.
The effect of rosuvastatin on serum lipid concentrations of
TC, LDL-C, HDL-C, TG and apolipoprotein B (Apo B) was
analysed. Adverse events, as indicated by ALT or AST five
times upper limit of normal (ULN) or CK ten times ULN
as well as any condition requiring discontinuation of the
drug, were documented.
Patients
161 patients seen in the IDC/HIVMC had been prescribed
rosuvastatin in dosages of 5,10,20 or 40 mg per day orally.
14 were excluded because exact start date of rosuvastatin
could not be determined and an additional 17 were
excluded because they lacked sufficient data for analysis
and 130 patients remained for analysis. Five patients dis-
continued rosuvastatin therapy due to adverse events. For
these patients their most recent lipid parameters prior to
discontinuation were used in study analyses. Concomi-
tant medications including other lipid lowering therapy,
namely cholesterol transport blockers (ezetimibe) and
fibrates (fenofibrate), and previous use of statins were
documented as well as each patient's current antiretroviral
regimen, simplified to either regimens containing pro-
tease inhibitors (PI) or those not containing protease
inhibitors (Non-PI).
Mean patient age was 52.6 ± 8.29 years, 128 (98.5%)
patients were male and 20 (15.4%) had diabetes mellitus.
The mean duration of rosuvastatin therapy was 140.8 ±
112.84 days. 78 (60.0%) patients had previously taken a
statin (64 atorvastatin, 10 pravastatin, 2 fluvastatin, 1
cerivastatin, 1 simvastatin) before being switched to rosu-
vastatin. 109 (83.8%) patients were on PI ARV regimens,
14 (10.8%) were on non-PI ARV regimens and 7 (5.4%)
were taking no ARV therapy.
Analysis/Ethics
Student's T-test for both paired and unpaired samples was
used to compare pre and post treatment differences and
subgroup differences, respectively.
Ethical approval was granted by the Research Ethics Board
at St. Paul's Hospital.
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